Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Tejedor, JR"'
Autor:
Tejedor, JR, Bueno, C, Cobo, I, Bayon, GF, Prieto, C, Mangas, C, Perez, RF, Santamarina, P, Urdinguio, RG, Menendez, P, Fraga, MF, Fernandez, AF
Publikováno v:
Epigenomics
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Aim: Epigenetic regulation plays an important role in cellular development and differentiation. A detailed map of the DNA methylation dynamics that occur during cell differentiation would contribute to decipher the molecular networks governing cell f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::f36f1d764cace7b18b0bb2c485015ccd
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5591
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=5591
Autor:
Maldonado, AM, Marqués, M, Martín, S, Hoffman, T, Tejedor, JR, Shen, M, Valcárcel, J, Real, FX
Publikováno v:
In Urologic Oncology: Seminars and Original Investigations December 2020 38(12):905-905
Autor:
Tejedor JR; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.; Health Research Institute of Asturias (ISPA), Foundation for Biomedical Research and Innovation in Asturias (FINBA), Principality of Asturias, Spain.; University Institute of Oncology of Asturias (IUOPA), Principality of Asturias, Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Soriano-Sexto A; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Molecular Disease Diagnostic Center (CEDEM), Department of Molecular Biology, Autonomous University of Madrid (UAM), Madrid, Spain.; Centre for Molecular Biology (CBMSO), Spanish National Research Council (CSIC), Madrid, Spain.; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain., Beccari L; Centre for Molecular Biology (CBMSO), Spanish National Research Council (CSIC), Madrid, Spain., Castejón-Fernández N; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Molecular Disease Diagnostic Center (CEDEM), Department of Molecular Biology, Autonomous University of Madrid (UAM), Madrid, Spain.; Centre for Molecular Biology (CBMSO), Spanish National Research Council (CSIC), Madrid, Spain.; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain., Correcher P; Nutrition and Metabolopathologies Unit, La Fe University Hospital, Valencia, Spain., Sainz-Ledo L; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.; Health Research Institute of Asturias (ISPA), Foundation for Biomedical Research and Innovation in Asturias (FINBA), Principality of Asturias, Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Alba-Linares JJ; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.; Health Research Institute of Asturias (ISPA), Foundation for Biomedical Research and Innovation in Asturias (FINBA), Principality of Asturias, Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Urdinguio RG; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.; Health Research Institute of Asturias (ISPA), Foundation for Biomedical Research and Innovation in Asturias (FINBA), Principality of Asturias, Spain.; University Institute of Oncology of Asturias (IUOPA), Principality of Asturias, Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Ugarte M; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Molecular Disease Diagnostic Center (CEDEM), Department of Molecular Biology, Autonomous University of Madrid (UAM), Madrid, Spain.; Centre for Molecular Biology (CBMSO), Spanish National Research Council (CSIC), Madrid, Spain.; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain., Fernández AF; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.; Health Research Institute of Asturias (ISPA), Foundation for Biomedical Research and Innovation in Asturias (FINBA), Principality of Asturias, Spain.; University Institute of Oncology of Asturias (IUOPA), Principality of Asturias, Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Rodríguez-Pombo P; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Molecular Disease Diagnostic Center (CEDEM), Department of Molecular Biology, Autonomous University of Madrid (UAM), Madrid, Spain.; Centre for Molecular Biology (CBMSO), Spanish National Research Council (CSIC), Madrid, Spain.; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain., Fraga MF; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Spanish National Research Council (CSIC), Principality of Asturias, Spain.; Health Research Institute of Asturias (ISPA), Foundation for Biomedical Research and Innovation in Asturias (FINBA), Principality of Asturias, Spain.; University Institute of Oncology of Asturias (IUOPA), Principality of Asturias, Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Pérez B; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Molecular Disease Diagnostic Center (CEDEM), Department of Molecular Biology, Autonomous University of Madrid (UAM), Madrid, Spain.; Centre for Molecular Biology (CBMSO), Spanish National Research Council (CSIC), Madrid, Spain.; Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
Publikováno v:
Journal of inherited metabolic disease [J Inherit Metab Dis] 2024 Dec 10. Date of Electronic Publication: 2024 Dec 10.
Autor:
Lopez-Millan B; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; GENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, Granada, Spain.; Department of Physiology, University of Granada, Granada, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Rubio-Gayarre A; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; GENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, Granada, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Vinyoles M; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Trincado JL; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Fraga MF; Fundación para la Investigación Biosanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Instituto Universitario de Oncología de Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Oviedo, Spain.; Nanomaterials and Nanotechnology Research Center, Universidad de Oviedo, Oviedo, Spain., Fernandez-Fuentes N; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Guerrero-Murillo M; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Martinez A; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Velasco-Hernandez T; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Falgàs A; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Panisello C; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain., Valcarcel G; Epigenetic Control of Hematopoiesis Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Sardina JL; Epigenetic Control of Hematopoiesis Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., López-Martí P; 3D Chromatin Organization Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Javierre BM; 3D Chromatin Organization Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain., Del Valle-Pérez B; Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques, Unitat Associada al Consejo Superior de Investigaciones Científicas, Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain., García de Herreros A; Programa de Recerca en Càncer, Institut Hospital del Mar d'Investigacions Mèdiques, Unitat Associada al Consejo Superior de Investigaciones Científicas, Departament de Medicina i Ciències de la Vida, Universitat Pompeu Fabra, Barcelona, Spain., Locatelli F; Department of Pediatric Hematology-Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, Bambino Gesù Children's Hospital, Rome, Italy., Pieters R; Princess Màxima Center for Pediatric Oncology, Utrecht, The Netherlands., Bardini M; Tettamanti Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy., Cazzaniga G; Tettamanti Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico San Gerardo dei Tintori, Monza, Italy.; School of Medicine and Surgery, University of Milan Bicocca, Monza, Italy., Rodríguez-Manzaneque JC; GENYO, Centre for Genomics and Oncological Research, Pfizer/Universidad de Granada/Junta de Andalucía, Granada, Spain., Hanewald T; Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe University of Frankfurt, Biocenter, Frankfurt/Main, Germany., Marschalek R; Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia, Goethe University of Frankfurt, Biocenter, Frankfurt/Main, Germany., Milne TA; Medical Research Council, Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, National Institute for Health and Care Research, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Stam RW; Princess Màxima Center for Pediatric Oncology, Utrecht, The Netherlands., Tejedor JR; Fundación para la Investigación Biosanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Instituto Universitario de Oncología de Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Oviedo, Spain.; Nanomaterials and Nanotechnology Research Center, Universidad de Oviedo, Oviedo, Spain., Menendez P; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain.; Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Barcelona, Spain.; Instituciò Catalana de Recerca i Estudis Avançats, Barcelona, Spain., Bueno C; Stem Cell Biology, Developmental Leukemia and Immunotherapy Group, Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Red Española de Terapias Avanzadas Network, Instituto de Salud Carlos III, Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer, Instituto de Salud Carlos III, Barcelona, Spain.
Publikováno v:
Blood [Blood] 2024 Nov 07; Vol. 144 (19), pp. 2002-2017.
Autor:
Peñarroya A; Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain., Lorca R; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.; Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain.; Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORs) Madrid Spain.; Departamento de Biología Funcional Universidad de Oviedo Oviedo Spain., Rodríguez Reguero JJ; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.; Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain., Gómez J; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.; Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain.; Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORs) Madrid Spain., Avanzas P; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.; Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain.; Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORs) Madrid Spain.; Departamento de Medicina Universidad de Oviedo Oviedo Spain.; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) Oviedo Spain., Tejedor JR; Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER) Madrid Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo Oviedo Asturias Spain., Fernandez AF; Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER) Madrid Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo Oviedo Asturias Spain., Fraga MF; Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.; Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER) Madrid Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo Oviedo Asturias Spain.
Publikováno v:
Journal of the American Heart Association [J Am Heart Assoc] 2024 Nov 05; Vol. 13 (21), pp. e035777. Date of Electronic Publication: 2024 Oct 29.
Autor:
Pérez RF; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain., Tezanos P; Departamento de Neurociencia Translacional, Instituto Cajal-Consejo Superior de Investigaciones Científicas (IC-CSIC), 28002, Madrid, Spain.; Programa de Doctorado en Neurociencia, Universidad Autónoma de Madrid-Instituto Cajal, 28002, Madrid, Spain., Peñarroya A; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain., González-Ramón A; Laboratory of Functional Epi-Genomics of Aging and Alzheimer's disease, Instituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), 03550, Alicante, Spain., Urdinguio RG; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain., Gancedo-Verdejo J; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain., Tejedor JR; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain., Santamarina-Ojeda P; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain., Alba-Linares JJ; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain., Sainz-Ledo L; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain., Roberti A; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain., López V; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain., Mangas C; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain., Moro M; Departamento de Neurociencia Translacional, Instituto Cajal-Consejo Superior de Investigaciones Científicas (IC-CSIC), 28002, Madrid, Spain., Cintado Reyes E; Departamento de Neurociencia Translacional, Instituto Cajal-Consejo Superior de Investigaciones Científicas (IC-CSIC), 28002, Madrid, Spain.; Programa de Doctorado en Neurociencia, Universidad Autónoma de Madrid-Instituto Cajal, 28002, Madrid, Spain., Muela Martínez P; Departamento de Neurociencia Translacional, Instituto Cajal-Consejo Superior de Investigaciones Científicas (IC-CSIC), 28002, Madrid, Spain.; Programa de Doctorado en Neurociencia, Universidad Autónoma de Madrid-Instituto Cajal, 28002, Madrid, Spain., Rodríguez-Santamaría M; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain.; Bioterio y unidad de imagen preclínica, Universidad de Oviedo, 33006, Oviedo, Spain., Ortea I; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Proteomics Unit, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), 33011, Oviedo, Spain., Iglesias-Rey R; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706, Santiago de Compostela, Spain., Castilla-Silgado J; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Departamento de Biología Funcional, Área de Fisiología, Universidad de Oviedo, 33006, Oviedo, Spain., Tomás-Zapico C; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Departamento de Biología Funcional, Área de Fisiología, Universidad de Oviedo, 33006, Oviedo, Spain., Iglesias-Gutiérrez E; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Departamento de Biología Funcional, Área de Fisiología, Universidad de Oviedo, 33006, Oviedo, Spain., Fernández-García B; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain.; Departamento de Biología Funcional, Área de Fisiología, Universidad de Oviedo, 33006, Oviedo, Spain., Sanchez-Mut JV; Laboratory of Functional Epi-Genomics of Aging and Alzheimer's disease, Instituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), 03550, Alicante, Spain., Trejo JL; Departamento de Neurociencia Translacional, Instituto Cajal-Consejo Superior de Investigaciones Científicas (IC-CSIC), 28002, Madrid, Spain., Fernández AF; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain. agustin.fernandez@cinn.es.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain. agustin.fernandez@cinn.es.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain. agustin.fernandez@cinn.es.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain. agustin.fernandez@cinn.es., Fraga MF; Cancer Epigenetics and Nanomedicine Laboratory, Centro de Investigación en Nanomateriales y Nanotecnología-Consejo Superior de Investigaciones Científicas (CINN-CSIC), Universidad de Oviedo, 33011, Oviedo, Spain. mffraga@cinn.es.; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA-FINBA), Universidad de Oviedo, 33011, Oviedo, Spain. mffraga@cinn.es.; Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Universidad de Oviedo, 33003, Oviedo, Spain. mffraga@cinn.es.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), 28029, Madrid, Spain. mffraga@cinn.es.; Departamento de Biología de Organismos y Sistemas, Área de Fisiología Vegetal, Universidad de Oviedo, 33006, Oviedo, Spain. mffraga@cinn.es.
Publikováno v:
Nature communications [Nat Commun] 2024 Jul 16; Vol. 15 (1), pp. 5829. Date of Electronic Publication: 2024 Jul 16.
Autor:
Bueno C; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.; Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain., Torres-Ruiz R; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.; Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.; Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain., Velasco-Hernandez T; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Molina O; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Petazzi P; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain., Martinez A; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Rodriguez V; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Vinyoles M; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain., Cantilena S; Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom., Williams O; Development Biology Cancer Program, Cancer Section, UCLGOS Institute of Child Health, London, United Kingdom., Vega-Garcia N; Hematology Laboratory, Hospital Sant Joan de Déu Barcelona, Barcelona, Spain.; Developmental Tumors Biology Group, Leukemia, and other Pediatric Hemopathies, Pediatric Cancer Center Barcelona, Institut de Recerca, Hospital Sant Joan de Déu, Barcelona, Spain., Rodriguez-Perales S; Molecular Cytogenetics and Genome Editing Unit, Human Cancer Genetics Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain., Segovia JC; Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.; Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain., Quintana-Bustamante O; Division of Hematopoietic Innovative Therapies, Biomedical Innovation Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain.; Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain., Roy A; MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.; Department of Pediatrics and National Institute for Health and Care Research Oxford Biomedical Research Centre Hematology Theme, University of Oxford, Oxford, United Kingdom., Meyer C; Diagnostic Center of Acute Leukemia-Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany., Marschalek R; Diagnostic Center of Acute Leukemia-Institute of Pharmaceutical Biology, Goethe-University, Frankfurt/Main, Germany., Smith AL; MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Milne TA; MRC Molecular Hematology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford Biomedical Research Center Hematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Fraga MF; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.; Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain.; Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain., Tejedor JR; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.; Cancer Epigenetics and Nanomedicine Laboratory, Nanomaterials and Nanotechnology Research Center, El Entrego, Spain.; Health Research Institute of Asturias, Institute of Oncology of Asturias and Department of Organisms and Systems Biology, University of Oviedo, Oviedo, Spain., Menéndez P; Stem Cell Biology, Immunotherapy and Developmental Leukemia Laboratory. Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Spanish Network for Advanced Therapies, Carlos III Health Institute, Barcelona, Spain.; Spanish Collaborative Cancer Network, Carlos III Health Institute, Barcelona, Spain.; Department of Biomedicine, University of Barcelona, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
Publikováno v:
Blood [Blood] 2023 Nov 16; Vol. 142 (20), pp. 1752-1756.
Autor:
Santamarina-Ojeda P; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Tejedor JR; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Principality of Asturias, Spain., Pérez RF; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Principality of Asturias, Spain., López V; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain., Roberti A; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain.; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Principality of Asturias, Spain., Mangas C; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain., Fernández AF; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Principality of Asturias, Spain., Fraga MF; Health Research Institute of Asturias (ISPA), Spain.; Foundation for Biomedical Research and Innovation in Asturias (FINBA), Spain.; University Institute of Oncology of Asturias (IUOPA), Spain.; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain.; Nanomaterials and Nanotechnology Research Centre (CINN-CSIC), Principality of Asturias, Spain.
Publikováno v:
Molecular oncology [Mol Oncol] 2023 Sep; Vol. 17 (9), pp. 1726-1743. Date of Electronic Publication: 2023 Jul 20.
DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.
Autor:
Cuesta-Borràs E; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Salvans C; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; University of Barcelona, Barcelona, Spain., Arqués O; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Chicote I; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; CIBERONC, 08029 Madrid, Spain., Ramírez L; Gastrointestinal and Endocrine Tumors Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Cabellos L; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Martínez-Quintanilla J; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Mur-Espinosa A; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; University of Barcelona, Barcelona, Spain., García-Álvarez A; Gastrointestinal and Endocrine Tumors Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Hernando J; Gastrointestinal and Endocrine Tumors Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Tejedor JR; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), Health Research Institute of the Principality of Asturias (ISPA), Spanish Biomedical Research Network in Rare Diseases (CIBERER), Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33011 Oviedo, Asturias, Spain., Mirallas O; Gastrointestinal and Endocrine Tumors Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Élez E; CIBERONC, 08029 Madrid, Spain; Gastrointestinal and Endocrine Tumors Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain., Fraga MF; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), Health Research Institute of the Principality of Asturias (ISPA), Spanish Biomedical Research Network in Rare Diseases (CIBERER), Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33011 Oviedo, Asturias, Spain., Tabernero J; CIBERONC, 08029 Madrid, Spain; Gastrointestinal and Endocrine Tumors Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; UVic-UCC, IOB-Quiron, 08023 Barcelona, Spain., Nuciforo P; CIBERONC, 08029 Madrid, Spain; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain., Capdevila J; Gastrointestinal and Endocrine Tumors Group, Medical Oncology Department, Vall d'Hebron University Hospital (HUVH), Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona (UAB), 08035 Barcelona, Spain; IOB-Teknon, 08023 Barcelona, Spain., Palmer HG; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; CIBERONC, 08029 Madrid, Spain. Electronic address: hgpalmer@vhio.net., Puig I; Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; CIBERONC, 08029 Madrid, Spain. Electronic address: ipuig@vhio.net.
Publikováno v:
Cell reports [Cell Rep] 2023 Aug 29; Vol. 42 (8), pp. 112927. Date of Electronic Publication: 2023 Aug 01.
Autor:
Tejedor JR; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER), 28029, Madrid, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., Peñarroya A; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain., Gancedo-Verdejo J; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER), 28029, Madrid, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., Santamarina-Ojeda P; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER), 28029, Madrid, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., Pérez RF; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER), 28029, Madrid, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., López-Tamargo S; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., Díez-Borge A; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Viralgen Vector Core, 20009, San Sebastián, Gipuzkoa, Spain., Alba-Linares JJ; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., González-Del-Rey N; Department of Organisms and Systems Biology, Institute of Biotechnology of Asturias, University of Oviedo, 33071, Oviedo, Asturias, Spain.; Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, 08028, Barcelona, Spain., Urdinguio RG; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Spanish Biomedical Research Network in Rare Diseases (CIBERER), 28029, Madrid, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., Mangas C; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., Roberti A; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain., López V; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain., Morales-Ruiz T; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), 14071, Córdoba, Spain.; Department of Genetics, University of Córdoba, 14071, Córdoba, Spain., Ariza RR; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), 14071, Córdoba, Spain.; Department of Genetics, University of Córdoba, 14071, Córdoba, Spain., Roldán-Arjona T; Maimónides Biomedical Research Institute of Córdoba (IMIBIC), 14071, Córdoba, Spain.; Department of Genetics, University of Córdoba, 14071, Córdoba, Spain., Meijón M; Department of Organisms and Systems Biology, Institute of Biotechnology of Asturias, University of Oviedo, 33071, Oviedo, Asturias, Spain., Valledor L; Department of Organisms and Systems Biology, Institute of Biotechnology of Asturias, University of Oviedo, 33071, Oviedo, Asturias, Spain., Cañal MJ; Department of Organisms and Systems Biology, Institute of Biotechnology of Asturias, University of Oviedo, 33071, Oviedo, Asturias, Spain., Fernández-Martínez D; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain.; Division of General Surgery, Department of Colorectal Surgery, Central University Hospital of Asturias (HUCA), 33011, Oviedo, Asturias, Spain., Fernández-Hevia M; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain.; Division of General Surgery, Department of Colorectal Surgery, Central University Hospital of Asturias (HUCA), 33011, Oviedo, Asturias, Spain., Jiménez-Fonseca P; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Division of Oncology, Department of Medical Oncology, Central University Hospital of Asturias (HUCA), 33011, Oviedo, Asturias, Spain., García-Flórez LJ; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain.; Division of General Surgery, Department of Colorectal Surgery, Central University Hospital of Asturias (HUCA), 33011, Oviedo, Asturias, Spain.; Department of Surgery and Medical Surgical Specialties, University of Oviedo, 33006, Oviedo, Asturias, Spain., Fernández AF; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain. agustin.fernandez@cinn.es.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain. agustin.fernandez@cinn.es.; Spanish Biomedical Research Network in Rare Diseases (CIBERER), 28029, Madrid, Spain. agustin.fernandez@cinn.es.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain. agustin.fernandez@cinn.es., Fraga MF; Nanomaterials and Nanotechnology Research Center (CINN), Spanish National Research Council (CSIC), 33940, El Entrego, Asturias, Spain. mffraga@cinn.es.; Health Research Institute of the Principality of Asturias (ISPA), Avenida de Roma S/N, 33011, Oviedo, Asturias, Spain. mffraga@cinn.es.; Spanish Biomedical Research Network in Rare Diseases (CIBERER), 28029, Madrid, Spain. mffraga@cinn.es.; Institute of Oncology of Asturias (IUOPA), University of Oviedo, 33006, Oviedo, Asturias, Spain. mffraga@cinn.es.
Publikováno v:
Clinical epigenetics [Clin Epigenetics] 2023 Aug 24; Vol. 15 (1), pp. 133. Date of Electronic Publication: 2023 Aug 24.